Generic Name and Formulations:
Zolpidem tartrate 5mg, 10mg; sublingual tabs.
Indications for EDLUAR:
≥18yrs: Use lowest effective dose. Place 1 tab under tongue and allow to dissolve; do not take with food, water, or alcohol. Initially 5mg (in women), and 5mg or 10mg (in men) at bedtime (take only if able to get 7–8hrs of sleep before becoming active again). Both: if 5mg dose ineffective, may increase to max 10mg. Elderly, debilitated, or hepatic impairment: 5mg once daily at bedtime. Effect delayed if taken with a meal.
<18yrs: not recommended.
Increased risk of next-day psychomotor impairment. Depression. Abnormal thinking and behavioral changes. Compromised respiratory function (eg, sleep apnea). Conditions that affect metabolism or hemodynamic response. Myasthenia gravis. Evaluate for co-morbid diagnoses before initiation. Reevaluate if insomnia persists after 7–10 days of use. Drug or alcohol abuse. Write Rx for smallest practical amount. Withdraw gradually. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Concomitant other sedative-hypnotics including other zolpidem products: not recommended. May potentiate CNS depression with alcohol, other CNS depressants (eg, benzodiazepines, opioids, tricyclics). May be potentiated by CYP3A4 inhibitors (eg, ketoconazole), sertraline. Decreased alertness with imipramine, chlorpromazine. May be antagonized by CYP3A4 inducers (eg, rifampin).
CNS effects (eg, hallucinations, agitation, behavioral changes, depersonalization, amnesia), complex sleep-related behaviors (eg, sleep-driving), headache, drowsiness, dizziness, diarrhea, anaphylaxis, angioedema; others.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- Young Fresh Frozen Plasma Infusion Safe, Feasible in Alzheimer Disease
- CBD Superior to Placebo, Similar to AEDs for Managing Epilepsy Syndromes
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?
- Hydrocephalus May Be a Complication of Congenial Zika Syndrome
- Higher CSF NfL Protein Levels Linked to Risk for Mild Cognitive Impairment
- Addressing Cognitive Impairment in Pediatric MS: Expert Q&A
- How the Government Shutdown Affects FDA Activities